期刊
HUMAN MOLECULAR GENETICS
卷 18, 期 16, 页码 3002-3013出版社
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddp238
关键词
-
资金
- Association pour la Recherche contre le Cancer [3734]
- Spanish Ministerio de Ciencia e Innovacion [CTQ2008-06866-C02-01, CTQ2008-02403/BQU]
- consolider-ingenio 2010 [CSD2007-00006]
The anti-Mullerian hormone type II (AMHRII) receptor is the primary receptor for anti-Mullerian hormone (AMH), a protein produced by Sertoli cells and responsible for the regression of the Mullerian duct in males. AMHRII is a membrane protein containing an N-terminal extracellular domain (ECD) that binds AMH, a transmembrane domain, and an intracellular domain with serine/threonine kinase activity. Mutations in the AMHRII gene lead to persistent Mullerian duct syndrome in human males. In this paper, we have investigated the effects of 10 AMHRII mutations, namely 4 mutations in the ECD and 6 in the intracellular domain. Molecular models of the extra- and intracellular domains are presented and provide insight into how the structure and function of eight of the mutant receptors, which are still expressed at the cell surface, are affected by their mutations. Interestingly, two soluble receptors truncated upstream of the transmembrane domain are not secreted, unless the transforming growth factor beta type II receptor signal sequence is substituted for the endogenous one. This shows that the AMHRII signal sequence is defective and suggests that AMHRII uses its transmembrane domain instead of its signal sequence to translocate to the endoplasmic reticulum, a characteristic of type III membrane proteins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据